爱科诺生物医药完成近亿元B+轮融资
爱科诺生物医药有限公司完成近亿元B+轮融资，由深创投领投，晨兴创投、领军创投和合肥创新投跟投。资金将用于推进炎症性肠病、银屑病等炎症与自身免疫疾病药物的临床开发。
媒体报道
「最新融资」爱科诺生物：完成近亿元B+轮融资，加速多个针对炎症及自身免疫性疾病候选药物的研发进程 医药魔方
爱科诺生物医药完成近亿元B+轮融资 界面
爱科诺生物医药完成近亿元B+轮融资，加速多个针对炎症及自身免疫性疾病候选药物的研发进程 医药魔方
#热门话题
BY Readhub
At a time when the Indian stock market is peaking and has rallied immensely compared to global markets, there are companies that have not performed in the last 10 years. These are definitely a minor portion of the market considering there are hundreds of stocks that have turned multibagger since 2020. What went wrong with these stocks? Reasons vary from corporate governance, sectoral weakness, company specific and so on. But the more important question is, are these stocks worth buying?
The S&P 500 slumped 1.8% on Monday and Tuesday, thanks to China Evergrande, the Chinese property company that looks like it is ready to default on its more-than $300 billion in debt. Cries of the next Lehman Brothers—or maybe the next Silverado?—echoed through the canyons of Wall Street as investors prepared for the worst.
Readhub from jp